"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...
Uro-G offers a viewing angle of 120°, both 210° upward and 130° downward motion angles, and a 90° angle of rotation clockwise and countercl...
It is a multi-center, open-label clinical study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab. Entry criteria include ...
The clinical trial is a multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-415 ...
Chief Executive John Lee met with H.E. Eng. Abdullah Al-Swaha, Minister of Communications and Information Technology of Kingdom of Saudi Arabia again fol...
STP122G is part of the Group's GalAhead™ Factor XI RNAi therapeutic program, which has applications across a broad range of disease indications such ...
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO...
On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...
Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...
Cancer is one of the leading causes of death across Asian countries. According to a report published by Janssen Asia Pacific, in 2017, overall, there wer...
Survey of 7,000+ people in Asia shows expectation of early retirement, early deterioration in health Concerns about cost of well-being nu...
Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "...
© 2023 Biopharma Boardroom. All Rights Reserved.
